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The receptor tyrosine kinase (RTK) Met
is the receptor for hepatocyte growth
factor/scatter factor (HGF/SF). Aberrant
signaling driven by inappropriate activa-
tion of Met is one of the most frequent
alterations observed in human cancers
and plays a crucial role in tumorigene-
sis and metastasis (Birchmeier et al.,
2003; Trusolino and Comoglio, 2002).
Inappropriate Met activation can arise
by ligand-dependent and -independent
mechanisms, which include overexpres-
sion of Met and/or HGF/SF, paracrine or
autocrine activation, or constitutive acti-
vation through gain-in-function muta-
tions. Activated Met recruits signaling
effectors to its multidocking site located
in the cytoplasmic domain (Figure 1),
resulting in the activation of several key
signaling pathways, including Ras-
MAPK, PI3K, Src, and Stat3. These
pathways are essential for tumor cell
proliferation, invasion, and angiogene-
sis, and for evading apoptosis. Targeting
the HGF/SF-Met pathway is becoming
an attractive approach for developing
therapeutic drugs that potentially would
have activity against a wide range of
human cancers (http://www.vai.org/vari/
metandcancer/index.aspx) by inhibiting
processes essential for malignant
growth.
In the past few years, many different
strategies have been developed to atten-
uate aberrant Met signaling in various
human cancer cells. These strategies
target, directly or indirectly, the Met
receptor and/or its ligand HGF/SF. As
depicted in Figure 1, direct methods
include: (1) neutralizing antibodies
against HGF/SF or the use of the
HGF/SF antagonist NK4 to prevent lig-
and access to Met (Cao et al., 2001;
Date et al., 1998), (2) dominant/negative
Met molecules or small molecule ATP
binding site inhibitors to Met that block
kinase activity (Furge et al., 2001;
Christensen et al., 2003), (3) engineered
SH2 domain polypeptides that interfere
with access to the multidocking site
(Atabey et al., 2001), and (4) RNAi or
ribozymes that reduce receptor or ligand
expression (N.S., unpublished data;
Abounader et al., 2002). Most of these
approaches display selective inhibition of
Met signaling. Indirect inhibition of Met
signaling can be achieved by blocking
Met downstream signaling pathways,
such as the MAPK, PI3K, or Stat3 path-
ways, which contribute to the malignant
features of Met (Birchmeier et al., 2003).
Small molecules such as geldanamycin
have also been shown to inhibit Met
(Webb et al., 2000).
In this issue of Cancer Cell, two
groups report that targeting the extracel-
lular domain of Met may be a promising
new approach for human cancer
intervention. Kong-Beltran et al. (2004)
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Inappropriate Met receptor tyrosine kinase signaling can produce proliferative, invasive, angiogenic, and antiapoptotic
activities that contribute to malignant growth. Met can be activated by paracrine or autocrine mechanisms in a ligand-
dependent fashion, or be constitutively activated by mutation and by other ligand-independent mechanisms. Because Met
is inappropriately expressed in almost all types of human cancer, the HGF/SF-Met signaling pathway should be an excep-
tional target for cancer intervention strategies and therapies. In this issue of Cancer Cell, two reports show that the extra-
cellular domain of Met is an important target for developing anticancer therapies.
Figure 1. Met receptor tyrosine kinase: Sites
and strategies for therapeutic intervention
Potential therapeutic strategies are: (1)
decoy Met receptor (decoy Met) or recom-
binant Met Sema domain (rSema) inhibit lig-
and (HGF/SF) binding and presumably Met
dimerization as well (decoy Met consists of
the entire extracellular region and rSema
consists of the Sema and PSI domains [see
right upper box]), (2) anti-Met antibodies
inhibit Met receptor dimerization and/or lig-
and binding, (3) HGF NK4 competes for HGF
binding of Met, (4) anti-HGF neutralizing anti-
bodies bind HGF and prevent Met stimula-
tion, (5) small molecule inhibitors or dominant
negative Met target the kinase domain and
inhibit Met phosphorylation/activation, (6)
SH2 domain competitors occupy the multi-
docking site and inhibit signal transduction,
(7) siRNA or ribozyme specific for Met or HGF
mRNA, (8) geldanamycin and derivatives
suppress Met activity presumably through
binding to Hsp90 and inhibiting molecular
chaperone function, and (9) potential small
molecule inhibitors or dominant negative
forms of downstream signaling molecule of
Met.
6 CANCER CELL : JULY 2004
demonstrate that Met can dimerize in an
HGF/SF-independent manner, and that
both receptor dimerization and ligand
binding requires the Sema domain.
These authors also provide evidence
that both recombinant Sema domain and
an anti-Met Fab recognizing the Sema
domain can inhibit Met activation in vitro.
By a similar approach, Michieli et al.
(2004) have engineered a soluble Met
consisting of the entire extracellular
region, called decoy Met, that is deliv-
ered in a lentivirus vector. Decoy Met
inhibits tumor growth and spontaneous
metastases of human xenografts in
immunocompromised mice. The most
interesting aspect of this decoy is its abil-
ity to inhibit HGF/SF-dependent as well
as HGF/SF-independent Met activation.
These data suggest that targeting the
extracellular region of Met can be an
alternative therapeutic strategy for treat-
ing human cancers by simultaneously
blocking the ligand binding as well as
presumably preventing receptor dimer-
ization.
It is noteworthy that decoy Met also
shows an inhibitory effect on Met-nega-
tive tumor xenograft growth by impairing
host Met-dependent angiogenesis.
However, this effect is transient, and
tumor cells eventually catch up to the
untreated tumors, suggesting that selec-
tion of an alternative signaling path-
way(s) may occur to enable tumor cells
to grow under less vascular environ-
ments. Therefore, the use of decoy Met
should only be considered in combina-
tion with inhibitors to the alternative sig-
naling pathway.
The Sema domain is required for
HGF/SF binding and Met dimerization,
but it is still not clear how it interferes with
the ligand receptor complex formation.
As with most targeted inhibitors, toxicity
related to expression of Met in normal
tissues may also be an issue. Met is a
member of a subfamily of receptor tyro-
sine kinases which includes Ron and
Sea, and the Sema domain is conserved
in all semaphorins and plexins (Trusolino
and Comoglio, 2002). This homology
with the receptor may lead to pleiotrophic
interactions. Therefore, additional in vivo
studies are required to address potential
toxicity. It is encouraging that toxicity
studies in mice by Michieli et al. showed
no adverse effects with long-term expo-
sure to decoy Met. However, the decoy
was human, not mouse Met, and speci-
ficity might be a factor in reducing toxici-
ty. Another issue is whether a lentiviral
vector is optimal, considering that the
viral vector can persist indefinitely and
viral integration would be undesirable. In
this regard, the recombinant Sema
domain or the Met Fab-recognizing
Sema domain would be a better choice
for therapy, yet in vivo activity needs to
be tested.
In the future, a complete image of
HGF/SF-Met complex by crystallization of
active HGF/SF with full-length Met recep-
tor will provide an even stronger structural
basis for designing new therapies. High-
resolution crystallographic images will
allow us to understand what residues are
required for the dimerization and ligand
binding in the Sema domain, how the
“activated” multidocking sites recruit
downstream molecules, and how the ATP
binding site in the kinase domain medi-
ates the intermolecular tyrosine phos-
phorylation. Peptidomimetic inhibitors or
other small molecules specifically target-
ing Met can be designed based on the
crystallographic knowledge, and this
could become a trend for future therapeu-
tic approaches. In such a way, small mole-
cule drugs that are easy to synthesize,
easy to modify, easy to deliver, and proba-
bly at low cost, would be advantageous.
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